Daiichi Sankyo To Stop Testing Inhaled Nafamostat In COVID-19 Patients In Japan

  • Daiichi Sankyo Co Ltd DSNKY said it was halting the development of an existing drug for the treatment of COVID-19 without citing a reason.
  • However, the Nikkei newspaper reported that there were safety concerns.
  • In March, the company started a Phase 1 trial in Japan of an inhaled form of nafamostat mesylate with COVID-19 patients.
  • Nafamostat is used in the treatment of pancreatitis and has antiviral properties.
  • Price Action: DSNKY closed at $23.76 on Monday.
Market News and Data brought to you by Benzinga APIs
Posted In: BiotechNewsHealth CareGeneralBriefsCovid-19COVID-19 Vaccine
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!